The global healthcare industry is transforming precision medicine and targeted therapies redefine the way complex diseases, especially cancer, are treated. One of the most promising innovations emerging from nuclear medicine is Radioligand Therapies (RLTs), a treatment modality that combines molecular targeting with radioactive isotopes to deliver radiation directly to cancer cells while minimizing damage to surrounding healthy tissue.
Radioligand therapies work by attaching a radioactive particle to a ligand, typically a small molecule, peptide, or antibody, that selectively binds to specific biomarkers expressed on tumor cells. Once administered into the bloodstr...
